Therapeutics targeting angiogenesis: Genetics and epigenetics, extracellular miRNAs and signaling networks (Review)

Katoh,Masaru

doi:10.3892/ijmm.2013.1444

Therapeutics targeting angiogenesis: Genetics and epigenetics, extracellular miRNAs and signaling networks (Review)

Authors:
- Masaru Katoh
View Affiliations

Affiliations: Division of Integrative Omics and Bioinformatics, National Cancer Center, Tokyo 104-0045, Japan
Published online on: July 16, 2013 https://doi.org/10.3892/ijmm.2013.1444
Pages: 763-767
Copyright: © Katoh . This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Angiogenesis is a process of neovascular formation from pre-existing blood vessels, which consists of sequential steps for vascular destabilization, angiogenic sprouting, lumen formation and vascular stabilization. Vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), angiopoietin, Notch, transforming growth factor-β (TGF-β), Hedgehog and WNT signaling cascades orchestrate angiogenesis through the direct or indirect regulation of quiescence, migration and the proliferation of endothelial cells. Small‑molecule compounds and human/humanized monoclonal antibodies interrupting VEGF signaling have been developed as anti‑angiogenic therapeutics for cancer and neovascular age-related macular degeneration (AMD). Gene or protein therapy delivering VEGF, FGF2 or FGF4, as well as cell therapy using endothelial progenitor cells (EPCs), mesenchymal stem cells (MSCs) or induced pluripotent stem cells (iPSCs) have been developed as pro‑angiogenic therapeutics for ischemic heart disease and peripheral vascular disease. Anti‑angiogenic therapy for cancer and neovascular AMD is more successful than pro‑angiogenic therapy for cardiovascular diseases, as VEGF‑signal interruption is technically feasible compared with vascular re‑construction. Common and rare genetic variants are detected using array-based technology and personal genome sequencing, respectively. Drug and dosage should be determined based on personal genotypes of VEGF and other genes involved in angiogenesis. As epigenetic alterations give rise to human diseases, polymer‑based hydrogel film may be utilized for the delivery of drugs targeting epigenetic processes and angiogenesis as treatment modalities for cardiovascular diseases. Circulating microRNAs (miRNAs) in exosomes and microvesicles are applied as functional biomarkers for diagnostics and prognostics, while synthetic miRNAs in polymer‑based nanoparticles are applicable for therapeutics. A more profound understanding of the spatio-temporal interactions of regulatory signaling cascades and advances in personal genotyping and miRNA profiling are required for the optimization of targeted therapy.

View Figures

View References

1	Carmeliet P: Angiogenesis in life, disease and medicine. Nature. 438:932–936. 2005. View Article : Google Scholar : PubMed/NCBI
2	Ferrara N and Kerbel RS: Angiogenesis as a therapeutic target. Nature. 438:967–974. 2005. View Article : Google Scholar : PubMed/NCBI
3	Folkman J: Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov. 6:273–286. 2007. View Article : Google Scholar : PubMed/NCBI
4	Carmeliet P and Jain RK: Molecular mechanisms and clinical applications of angiogenesis. Nature. 473:298–307. 2011. View Article : Google Scholar : PubMed/NCBI
5	Gaengel K, Genové G, Armulik A and Betsholtz C: Endothelial-mural cell signaling in vascular development and angiogenesis. Arterioscler Thromb Vasc Biol. 29:630–638. 2009. View Article : Google Scholar : PubMed/NCBI
6	Coultas L, Chawengsaksophak K and Rossant J: Endothelial cells and VEGF in vascular development. Nature. 438:937–945. 2005. View Article : Google Scholar : PubMed/NCBI
7	Olsson AK, Dimberg A, Kreuger J and Claesson-Welsh L: VEGF receptor signalling-in control of vascular function. Nat Rev Mol Cell Biol. 7:359–371. 2006. View Article : Google Scholar : PubMed/NCBI
8	Presta M, Dell’Era P, Mitola S, et al: Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 16:159–178. 2005. View Article : Google Scholar : PubMed/NCBI
9	Fagiani E and Christofori G: Angiopoietins in angiogenesis. Cancer Lett. 328:18–26. 2013. View Article : Google Scholar
10	Bridges E, Oon CE and Harris A: Notch regulation of tumor angiogenesis. Future Oncol. 7:569–588. 2011. View Article : Google Scholar
11	Katoh M and Katoh M: WNT signaling pathway and stem cell signaling network. Clin Cancer Res. 13:4042–4045. 2007. View Article : Google Scholar : PubMed/NCBI
12	Katoh Y and Katoh M: Hedgehog signaling, epithelial-to-mesenchymal transition and miRNA (Review). Int J Mol Med. 22:271–275. 2008.PubMed/NCBI
13	Rivkin E, Almeida SM, Ceccarelli DF, et al: The linear ubiquitin-specific deubiquitinase gumby regulates angiogenesis. Nature. 498:318–324. 2013. View Article : Google Scholar : PubMed/NCBI
14	Diehl AM: Neighborhood watch orchestrates liver regeneration. Nat Med. 18:497–499. 2012. View Article : Google Scholar : PubMed/NCBI
15	Katoh M and Nakagama H: FGF receptors: cancer biology and therapeutics. Med Res Rev. May 21–2013.(Epub ahead of print).
16	Dewhirst MW, Cao Y and Moeller B: Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer. 8:425–437. 2008. View Article : Google Scholar : PubMed/NCBI
17	Bao B, Azmi AS, Ali S, et al: The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness. Biochim Biophys Acta. 1826:272–296. 2012.PubMed/NCBI
18	Ferrara N, Hillan KJ and Novotny W: Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 333:328–335. 2005. View Article : Google Scholar : PubMed/NCBI
19	Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell-lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
20	Schmitt J and Matei D: Targeting angiogenesis in ovarian cancer. Cancer Treat Rev. 38:272–283. 2012. View Article : Google Scholar
21	Hall M, Gourley C, McNeish I, et al: Targeted anti-vascular therapies for ovarian cancer: current evidence. Br J Cancer. 108:250–258. 2013. View Article : Google Scholar : PubMed/NCBI
22	Chow LQ and Eckhardt SG: Sunitinib: from rational design to clinical efficacy. J Clin Oncol. 25:884–896. 2007. View Article : Google Scholar : PubMed/NCBI
23	Wilhelm SM, Adnane L, Newell P, et al: Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 7:3129–3140. 2008. View Article : Google Scholar : PubMed/NCBI
24	Shojaei F: Anti-angiogenesis therapy in cancer: current challenges and future perspectives. Cancer Lett. 320:130–137. 2012. View Article : Google Scholar : PubMed/NCBI
25	Bertolini F, Marighetti P, Martin-Padura I, et al: Anti-VEGF and beyond: shaping a new generation of anti-angiogenic therapies for cancer. Drug Discov Today. 16:1052–1060. 2011. View Article : Google Scholar : PubMed/NCBI
26	Konecny GE, Kolarova T, O’Brien NA, et al: Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells. Mol Cancer Ther. 12:632–42. 2013. View Article : Google Scholar : PubMed/NCBI
27	O’Hare T, Shakespeare WC, Zhu X, et al: AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 16:401–412. 2009.PubMed/NCBI
28	Gavine PR, Mooney L, Kilgour E, et al: AZD4547: An orally bioavailable, potent and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 72:2045–2056. 2012. View Article : Google Scholar : PubMed/NCBI
29	Chen HX and Cleck JN: Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol. 6:465–477. 2009. View Article : Google Scholar : PubMed/NCBI
30	Penn JS, Madan A, Caldwell RB, et al: Vascular endothelial growth factor in eye disease. Prog Retin Eye Res. 27:331–371. 2008. View Article : Google Scholar : PubMed/NCBI
31	Rajagopalan S, Mohler ER 3rd, Lederman RJ, et al: Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation. 108:1933–1938. 2003.
32	Roth DA, McKirnan MD, Canestrelli I, et al: Intracoronary delivery of an adenovirus encoding fibroblast growth factor-4 in myocardial ischemia: effect of serum antibodies and previous exposure to adenovirus. Hum Gene Ther. 17:230–238. 2006. View Article : Google Scholar
33	Sarkar N, Rück A, Källner G, et al: Effects of intramyocardial injection of phVEGF-A165 as sole therapy in patients with refractory coronary artery disease-12-month follow-up: angiogenic gene therapy. J Intern Med. 250:373–381. 2001. View Article : Google Scholar : PubMed/NCBI
34	Belch J, Hiatt WR, Baumgartner I, et al: Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia. Lancet. 377:1929–1937. 2011. View Article : Google Scholar : PubMed/NCBI
35	Formiga FR, Tamayo E, Simón-Yarza T, et al: Angiogenic therapy for cardiac repair based on protein delivery systems. Heart Fail Rev. 17:449–473. 2012. View Article : Google Scholar : PubMed/NCBI
36	Hoare TR and Kohane DS: Hydrogels in drug delivery: Progress and challenges. Polymer. 49:1993–2007. 2008. View Article : Google Scholar
37	Aranguren XL, McCue JD, Hendrickx B, et al: Multipotent adult progenitor cells sustain function of ischemic limbs in mice. J Clin Invest. 118:505–514. 2008.PubMed/NCBI
38	da Meirelles LS, Fontes AM, Covas DT and Caplan AI: Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev. 20:419–427. 2009.
39	Suzuki H, Shibata R, Kito T, et al: Comparative angiogenic activities of induced pluripotent stem cells derived from young and old mice. PLoS One. 7:e395622012. View Article : Google Scholar : PubMed/NCBI
40	Lichtenstein P, Holm NV, Verkasalo PK, et al: Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 343:78–85. 2000. View Article : Google Scholar
41	Zimmet P, Alberti KG and Shaw J: Global and societal implications of the diabetes epidemic. Nature. 414:782–787. 2001. View Article : Google Scholar : PubMed/NCBI
42	Eechoute K, van der Veldt AA, Oosting S, et al: Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension. Clin Pharmacol Ther. 92:503–510. 2012.PubMed/NCBI
43	Scartozzi M, Bianconi M, Faloppi L, et al: VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib. Br J Cancer. 108:1126–1132. 2013.PubMed/NCBI
44	Petrovič MG, Korošec P, Košnik M, et al: Local and genetic determinants of vascular endothelial growth factor expression in advanced proliferative diabetic retinopathy. Mol Vis. 14:1382–1387. 2008.PubMed/NCBI
45	Miles DW, de Haas SL, Dirix LY, et al: Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. Br J Cancer. 108:1052–1060. 2013. View Article : Google Scholar : PubMed/NCBI
46	Baylin SB and Jones PA: A decade of exploring the cancer epigenome-biological and translational implications. Nat Rev Cancer. 11:726–734. 2011. View Article : Google Scholar : PubMed/NCBI
47	Ordovás JM and Smith CE: Epigenetics and cardiovascular disease. Nat Rev Cardiol. 7:510–519. 2010.
48	Issa JP, Ahuja N, Toyota M, et al: Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res. 61:3573–3577. 2001.PubMed/NCBI
49	Kang GH, Lee HJ, Hwang KS, et al: Aberrant CpG island hypermethylation of chronic gastritis, in relation to aging, gender, intestinal metaplasia, and chronic inflammation. Am J Pathol. 163:1551–1556. 2003. View Article : Google Scholar : PubMed/NCBI
50	Rivenbark AG and Coleman WB: Field cancerization in mammary carcinogenesis - Implications for prevention and treatment of breast cancer. Exp Mol Pathol. 93:391–398. 2012. View Article : Google Scholar : PubMed/NCBI
51	Wittmann J and Jäck HM: Serum microRNAs as powerful cancer biomarkers. Biochim Biophys Acta. 1806:200–207. 2010.PubMed/NCBI
52	Kuehbacher A, Urbich C and Dimmeler S: Targeting microRNA expression to regulate angiogenesis. Trends Pharmacol Sci. 29:12–15. 2008. View Article : Google Scholar
53	Wang S and Olson EN: AngiomiRs - key regulators of angiogenesis. Curr Opin Genet Dev. 19:205–211. 2009. View Article : Google Scholar
54	Gallo A, Tandon M, Alevizos I and Illei GG: The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. PLoS One. 7:e306792012. View Article : Google Scholar : PubMed/NCBI
55	Turchinovich A, Weiz L and Burwinkel B: Extracellular miRNAs: the mystery of their origin and function. Trends Biochem Sci. 37:460–465. 2012. View Article : Google Scholar : PubMed/NCBI
56	Banigan MG, Kao PF, Kozubek JA, et al: Differential expression of exosomal microRNAs in prefrontal cortices of schizophrenia and bipolar disorder patients. PLoS One. 8:e488142013. View Article : Google Scholar : PubMed/NCBI
57	Cantaluppi V, Gatti S, Medica D, et al: Microvesicles derived from endothelial progenitor cells protect the kidney from ischemia-reperfusion injury by microRNA-dependent reprogramming of resident renal cells. Kidney Int. 82:412–427. 2012. View Article : Google Scholar
58	Lässer C: Exosomal RNA as biomarkers and the therapeutic potential of exosome vectors. Expert Opin Biol Ther. 12(Suppl 1): S189–S197. 2012.PubMed/NCBI
59	Qin D, Trenkwalder T, Lee S, et al: Early vessel destabilization mediated by Angiopoietin-2 and subsequent vessel maturation via Angiopoietin-1 induce functional neovasculature after ischemia. PLoS One. 8:e618312013. View Article : Google Scholar